Study reveals how fast weight returns after ending GLP-1 drugs
Post Content
Novo Nordisk Gets Discounted as Investors Look Past the Next Phase of GLP-1 Growth
George Mason trial: New pill aims to sustain weight loss after GLP-1s
GLP-1 medications like Ozempic and Wegovy have transformed obesity treatment, but maintaining weight loss after the medications stop remains a challenge.
Joel Habener, Whose Research Led to Weight-Loss Drugs, Dies at 88
His discovery of the protein fragment GLP-1 was crucial in the development of Ozempic, Wegovy and other blockbuster obesity and diabetes treatments.
You’re Doing This Right — And Still Not Burning Fat | Dr. Mandell
Many people eat healthy, cut sugar, and still struggle with stubborn fat, low energy, or blood sugar swings. In this video, Dr. Mandell explains why fat loss is not just about what you eat, but how your body interprets a meal at the physiological level. Learn how eating speed influences digestion, insulin signaling, cortisol, and […]
Novo Nordisk’s (NVO)
Novo Nordisk’s (NVO) Novo Nordisk A/S Sponsored ADR Class B BATS:NVO KalaGhazi Based on a detailed technical analysis of Novo Nordisk’s (NVO) stock in the context of its recent groundbreaking commercial and regulatory developments, including the U.S. launch of the oral Wegovy pill and its availability on Amazon Pharmacy, several key Fibonacci retracement levels have […]
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
Johnson & Johnson JNJ recently signed a landmark agreement with the Trump administration to lower drug prices in the United States. Following this deal, JNJ joins several other large-cap pharma companies that signed similar deals with the government in 2025. These companies include Amgen, Bristol Myers, privately-held Boehringer Ingelheim, Genentech (a member of the Roche Group), Gilead Sciences, GSK […]
Amylyx selects AMX-0318 as development candidate
Amylyx Pharmaceuticals Inc. has nominated AMX-0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases.
Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond
2025 was a tumultuous year for the global healthcare sector. For much of the year, policy uncertainty, particularly around U.S. drug pricing and trade barriers, weighed heavily on valuations, which reached near 30-year lows (as mentioned by a BlackRock report). However, a dramatic shift occurred in the final quarter. The sector rebounded strongly, led by […]
THE WORLD IS FLAT FAT: More than a quarter of adults worldwide could benefit from GLP-1 medications
THE WORLD IS FLAT FAT: More than a quarter of adults worldwide could benefit from GLP-1 medications for weight loss, study finds.